Given the emerging concept of polypharmacology, and the growing interest in multitarget drugs as therapeutic agents, it will be interesting to know if MYB inhibitory and anti-microtubule activities both contribute to the ability of the compound to preferentially suppress the proliferation of AML and ACC cells. Here, MYB is linked to acute myeloid leukemia.